- Home
- MIRM vs JBLU Comparison
MIRM vs JBLU Comparison
Compare MIRM & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- JBLU
- Stock Information
- Founded
- MIRM 2018
- JBLU 1998
- Country
- MIRM United States
- JBLU United States
- Employees
- MIRM N/A
- JBLU N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- JBLU Air Freight/Delivery Services
- Sector
- MIRM Health Care
- JBLU Consumer Discretionary
- Exchange
- MIRM Nasdaq
- JBLU Nasdaq
- Market Cap
- MIRM 2.1B
- JBLU 2.1B
- IPO Year
- MIRM 2019
- JBLU N/A
- Fundamental
- Price
- MIRM $46.95
- JBLU $7.64
- Analyst Decision
- MIRM Strong Buy
- JBLU Sell
- Analyst Count
- MIRM 11
- JBLU 12
- Target Price
- MIRM $57.00
- JBLU $6.55
- AVG Volume (30 Days)
- MIRM 450.2K
- JBLU 15.3M
- Earning Date
- MIRM 02-26-2025
- JBLU 01-28-2025
- Dividend Yield
- MIRM N/A
- JBLU N/A
- EPS Growth
- MIRM N/A
- JBLU N/A
- EPS
- MIRM N/A
- JBLU N/A
- Revenue
- MIRM $307,028,000.00
- JBLU $9,327,000,000.00
- Revenue This Year
- MIRM $82.14
- JBLU N/A
- Revenue Next Year
- MIRM $26.18
- JBLU $5.02
- P/E Ratio
- MIRM N/A
- JBLU N/A
- Revenue Growth
- MIRM 112.14
- JBLU N/A
- 52 Week Low
- MIRM $23.14
- JBLU $4.50
- 52 Week High
- MIRM $48.89
- JBLU $8.28
- Technical
- Relative Strength Index (RSI)
- MIRM 65.98
- JBLU 55.35
- Support Level
- MIRM $40.55
- JBLU $7.40
- Resistance Level
- MIRM $47.25
- JBLU $7.94
- Average True Range (ATR)
- MIRM 1.49
- JBLU 0.37
- MACD
- MIRM 0.56
- JBLU -0.05
- Stochastic Oscillator
- MIRM 95.52
- JBLU 41.82
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.